D.Western Therapeutics Institute, Inc.
4576・Growth Market・Pharmaceuticals
Business
D. Western Therapeutics Institute, Inc. is a drug discovery biotech venture that conducts research and development of pharmaceuticals centered on protein kinase inhibitors, guided by its vision of "delivering groundbreaking new drugs from Japan to the world." The company focuses on ophthalmic diseases as its main field, holding multiple development pipelines targeting glaucoma, Fuchs' endothelial corneal dystrophy, bullous keratopathy, neuropathic pain, and other conditions. It operates its business through a two-company structure together with its consolidated subsidiary, Nippon Innovative Pharma Inc., and has products already on the market, including Glanatec Ophthalmic Solution (launched domestically), Glanatec Alpha® Combination Ophthalmic Solution (launched domestically and in Asia), and ILM-Blue. Development products are licensed out to pharmaceutical companies such as Kowa, DORC, Rohto Pharmaceutical, and Wakamoto Pharmaceutical, with royalty income serving as the main source of revenue.
Business Model
The company licenses out compounds to pharmaceutical companies and others at a relatively early development stage following basic research, earning revenue through a three-tier structure: front money income upon contract execution, milestone income based on clinical development progress, and royalty income linked to sales after product launch. Since R&D costs for licensed-out pipeline products are borne by the licensee, the company can pursue development of multiple products in parallel while keeping its own costs down. Revenue of ¥387 million in FY2025 (ending December 2025) consisted almost entirely of royalty income, with the main counterparties being DORC (84.4% of revenue) and Kowa (15.5%).
Company Strengths
The proprietary Drug Western method developed in-house enables identification of numerous target proteins in a single screening. It offers advantages such as low consumption of biological materials and compounds, simple operation, and short completion time, functioning as a unique platform technology that enhances the efficiency of creating new drug candidate compounds with high efficacy and safety.
The company continuously earns royalty income from multiple marketed products, including Glanatec, Glanatec Alpha® Combination Ophthalmic Solution, and ILM-Blue. In addition, it holds multiple items at different development stages, such as K-321 (Phase III), DW-5LBT (already approved in the U.S.), DWR-2206 (Phase II completed), and H-1337 (late-stage Phase II completed), forming a foundation for revenue diversification.
Since 2010, the company has utilized an industry-academia-government collaborative course with Mie University, a national university corporation (contract continuing through December 2026), advancing R&D without owning its own research facilities. By actively utilizing external CROs and outsourcing partners, the company suppresses increases in fixed costs while continuing to explore new drug candidate compounds primarily for ophthalmology-related diseases.
ENVALITH's Perspective
Performance Trend
Revenue for Q1 FY2026 (January-March 2026) was ¥15 million (versus ¥96 million in the same period of the previous year, a decrease of 84.4% year-on-year), operating loss was ¥167 million (versus ¥142 million in the same period of the previous year), ordinary loss was ¥170 million (versus ¥149 million in the same period of the previous year), and quarterly net loss was ¥170 million (versus ¥150 million in the same period of the previous year). The significant decline in revenue was primarily due to royalties not being recorded because contract extension negotiations with DORC regarding TissueBlue™ were still ongoing, while sales of Glanatec Alpha® Combination Ophthalmic Solution progressed smoothly in Japan and Asia. Selling, general and administrative expenses were reduced to ¥182 million (a decrease of 20.2% year-on-year), with research and development expenses at ¥117 million (a decrease of 17.5% year-on-year) and other SG&A expenses at ¥64 million (a decrease of 24.7% year-on-year). The full-year earnings forecast remains unchanged at revenue of ¥300 million, operating loss of ¥780 million, and net loss of ¥800 million. In the financial trends over the past five fiscal years, operating loss peaked at ¥1,210 million in FY2024, then narrowed to ¥620 million in FY2025; however, the loss for Q1 FY2026 expanded year-on-year, and the completion of the TissueBlue™ contract extension holds the key to full-year performance.
Growth Strategy
Enhancing corporate value through pipeline approval application progress, licensing revenue maximization, and strategic capital alliances
For DWR-2206 (Bullous Keratopathy Therapeutic Agent) K-321, the entire observation period of the global Phase III clinical trial was completed in March 2026, and data analysis is currently underway. Following completion of the analysis, Kowa is expected to file for approval in the United States, Europe, and other regions, and milestone revenue from the filing and approval is anticipated.
An agreement has been reached with DORC regarding the contract extension for regions where patents remain in force, and details such as terms and conditions are currently under discussion. Once the contract extension is finalized, unrecorded royalties—including those for the first quarter of 2026—are expected to be recognized in a lump sum, which is a key premise for achieving full-year net sales of ¥300 million.
In March 2026, an option agreement covering Japan, Asia, and other regions was concluded with Senju Pharmaceutical, and an investment of approximately ¥200 million was received. The policy has shifted to prioritizing development in Japan, and preparations for a Phase III clinical trial are proceeding in collaboration with Senju Pharmaceutical. Development in the United States will be reconsidered in light of the situation in Japan.
A Phase III clinical trial (conducted by Wakamoto Pharmaceutical) for internal limiting membrane staining and anterior lens capsule staining using DW-1002 (Brilliant Blue G / Brilliant Blue G・Trypan Blue) is underway in Japan. The Brilliant Blue G/Trypan Blue combination product for the United States (DORC) is in application preparation, with the aim of establishing a new royalty revenue source upon approval.
The company continues to raise funds through a combination of borrowings from its main financial institutions, a third-party allotment of shares (2,150,500 shares allotted to Senju Pharmaceutical, with payment completed in April 2026), and the exercise of stock acquisition rights, among other measures. Cash and deposits at the end of the first quarter of 2026 stood at ¥1,539 million, securing near-term research and development funding.
Last updated: July 17, 2026